Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
Anna Maria FrezzaTarek AssiSalvatore Lo VulloEytan Ben-AmiArmelle DufresneKan YonemoriEmi NoguchiBrittany SiontisRichard FerraroPawel TeteryczFlorence DuffaudVinod RaviBruno VincenziHans GelderblomMaria A PantaleoGiacomo G BaldiIngrid DesarAlexander FedenkoRobert G MakiRobin L JonesRobert S BenjaminJean Yves BlayAkira KawaiMrinal GounderAlessandro GronchiAxel Le CesneOlivier MirAnna M CzarneckaScott SchuetzeAndrew J WagnerJulien AdamMarta BarisellaMarta SbaragliaJason L HornickAlexandra MeurgeyLuigi MarianiPaolo G CasaliKatherine ThorntonSilvia StacchiottiPublished in: Cancer (2019)
This retrospective series shows the activity of anthracycline-based regimens in InS. Of note, anthracyclines were used in patients with cardiac InS with no significant cardiac toxicity. The prognosis in patients with InS remains poor, and new active drugs and treatment strategies are needed.